Otomikosis

01Pathophysiology

Otomycosis is a superficial fungal infection of the external auditory canal. It accounts for approximately 9% of all otitis externa cases in temperate climates and up to 30% or more in tropical and subtropical regions.

The external auditory canal normally maintains a slightly acidic pH (approximately 5.0 to 5.7) through cerumen production. Cerumen contains lysozyme, immunoglobulins, and saturated fatty acids that collectively create an environment hostile to both bacterial and fungal colonization. When this protective barrier is disrupted, the canal becomes vulnerable to opportunistic fungal colonization.

The most common mechanism of disruption is prolonged use of topical antibiotic ear drops, which eliminates the competing bacterial flora and shifts the canal microenvironment in favor of fungal overgrowth. This is why otomycosis frequently follows a course of treatment for bacterial otitis externa. Similarly, topical corticosteroid drops suppress the local immune response, further facilitating fungal invasion.

Moisture retention is the second critical pathophysiological driver. The ear canal is a warm, enclosed space. When external factors such as swimming, humid climate, hearing aids, or occlusive earplugs trap moisture, the canal becomes an ideal incubator for fungal growth. Fungi require moisture and warmth to germinate, and the EAC provides both.

Once fungi colonize the canal epithelium, they produce a dense mat of hyphae and spores that sits on the skin surface and invades the superficial keratinized layers. This fungal biofilm triggers a localized inflammatory response, leading to edema, erythema, and exudation. The inflammatory exudate mixes with desquamated epithelium and fungal elements to create the characteristic thick, cottage-cheese-like or wet newspaper debris seen on otoscopy.

The hallmark symptom of intense pruritus results from the superficial epithelial invasion and the release of fungal proteases and inflammatory mediators at the skin surface. Pain in otomycosis tends to be milder than in bacterial otitis externa because the infection is more superficial; however, when secondary bacterial superinfection occurs, pain can become severe.

Conductive hearing loss develops when the fungal mass and associated debris physically obstruct the canal, preventing sound transmission to the tympanic membrane.

02Classification and Clinical Manifestation

By Causative Organism

By Severity

Clinical Manifestation Summary

03Diagnostic Workup

The diagnosis of otomycosis is primarily clinical, based on a thorough history and otoscopic examination. In the majority of cases, the otoscopic appearance is sufficiently distinctive that further testing is not required to initiate treatment.

Otoscopy is the best initial test and the cornerstone of diagnosis. The examiner looks for the hallmark findings: a mass of fungal debris in the EAC that may appear as white cottony filaments, black dot-like spore heads on a gray background ("salt and pepper" or "wet newspaper" pattern for Aspergillus), or a creamy-white thick paste-like discharge for Candida. The canal skin is typically erythematous and edematous, and the tympanic membrane may be partially or completely obscured by the fungal mass. If the membrane is visible, it may appear thickened, dull, or inflamed.

When the clinical presentation is ambiguous or the infection is recurrent or refractory to treatment, KOH (potassium hydroxide) wet mount should be performed on a sample of canal debris. KOH dissolves keratin and cellular debris, allowing clear visualization of fungal elements under microscopy. Septate hyphae with dichotomous branching at 45-degree angles are characteristic of Aspergillus species. Budding yeast cells with pseudohyphae indicate Candida.

Fungal culture on Sabouraud Dextrose Agar (SDA) is the gold standard for definitive species identification. This test is most important in recurrent, refractory, or immunocompromised cases where antifungal susceptibility testing may guide therapy. Culture results take 1 to 4 weeks, so treatment should not be delayed while awaiting results.

It is important to distinguish otomycosis from bacterial otitis externa and from malignant (necrotizing) otitis externa in diabetic or immunocompromised patients. If granulation tissue is seen at the bony-cartilaginous junction or if there is evidence of bony erosion, CT imaging of the temporal bone should be obtained to evaluate for necrotizing otitis externa.

04Management and Treatment

Step 1: Aural Toilet (First Step)

The single most important intervention is thorough mechanical debridement of all fungal debris from the external auditory canal. This must be performed before applying any topical agent, because antifungal drops or creams cannot penetrate a thick fungal mat. Debridement is ideally done under direct visualization using an operating microscope or otoscope with suction microaspiration. Dry mopping with cotton-tipped applicators is an alternative in resource-limited settings. Aural toilet should be repeated at follow-up visits, as residual fungal elements are a common cause of recurrence.

Step 2: Topical Antifungal Therapy (Mainstay of Treatment)

After thorough cleaning, the first-line agent is clotrimazole 1% solution, applied as ear drops or directly to the canal wall 2 to 3 times daily for a minimum of 2 to 3 weeks. Clotrimazole has broad-spectrum activity against both Aspergillus and Candida species, making it the preferred empiric choice. Treatment should continue for at least 1 week beyond clinical resolution to reduce relapse risk.

An alternative is miconazole 2% cream, which is applied similarly. For mild cases or as an adjunct, acetic acid 2% drops (such as Burow solution) can be used to restore the acidic canal pH and create an environment unfavorable for fungal growth. Acetic acid is dosed as 3 to 4 drops, 3 times daily.

If Candida is the identified or suspected pathogen, nystatin otic drops are effective, although nystatin has limited activity against Aspergillus species.

Step 3: Discontinue Offending Agents

If the patient is currently using topical antibiotic or corticosteroid ear drops, these should be discontinued, as they are often the precipitating cause of the fungal infection. This is a commonly tested management point.

Step 4: Keep the Ear Canal Dry

Patients should be counseled to avoid water entry into the affected ear. Strategies include using a cotton ball coated with petroleum jelly while showering and avoiding swimming until the infection has fully resolved. Hearing aid use should be suspended during treatment, as it traps moisture and serves as a reservoir for fungal re-inoculation.

Step 5: Systemic Antifungal Therapy (Reserved for Refractory Cases)

Oral antifungals are not first-line therapy. They are reserved for:

• Recurrent or refractory otomycosis despite adequate topical therapy and aural toilet

• Immunocompromised patients (e.g., uncontrolled diabetes, HIV/AIDS)

• Cases with suspected invasive extension

Oral itraconazole at 100 mg twice daily for 2 to 4 weeks is the preferred systemic agent for Aspergillus-dominant disease. Oral fluconazole at 50 to 100 mg once daily for 2 to 4 weeks is preferred for Candida-dominant cases. Liver function should be monitored during systemic azole therapy.

Contraindications and Cautions:

• Topical antifungals should be used with caution if a tympanic membrane perforation is present. Many topical antifungal preparations are potentially ototoxic when they reach the middle ear. Clotrimazole is generally considered safer in this setting, but referral to an otolaryngologist is appropriate.

• Systemic azoles interact with numerous medications (warfarin, statins, benzodiazepines) via CYP450 inhibition. Always review the drug interaction profile before prescribing.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get otomycosis questions wrong is by treating it identically to bacterial otitis externa. A vignette will describe a patient who was recently treated with antibiotic ear drops for otitis externa, improved briefly, and then returned with worsening pruritus and a new "dark/cottage-cheese" discharge. The trap answer is to prescribe another round of antibiotic drops. The correct answer is to recognize the post-antibiotic shift to fungal overgrowth and treat with topical antifungal therapy after aural toilet.

A second common trap involves the patient with diabetes or immunosuppression who presents with ear canal pain and granulation tissue. Students may default to otomycosis because they associate immunocompromised states with fungal infection. However, the presence of granulation tissue at the bony-cartilaginous junction with cranial nerve involvement should immediately redirect the answer to malignant (necrotizing) otitis externa, a far more dangerous diagnosis caused by Pseudomonas aeruginosa.

The third frequently tested concept is the role of aural toilet. Exam questions may present a patient with confirmed otomycosis who has failed topical antifungal therapy. The next best step is not to escalate to oral antifungals but rather to perform thorough mechanical debridement of the canal. Without removing the fungal mat, topical agents cannot reach the canal epithelium. Aural toilet is both the first and the most important step.

The core competency being tested across otomycosis questions is the ability to distinguish fungal from bacterial external ear infections based on symptom profile (pruritus vs. pain), otoscopic appearance (fungal debris vs. purulent discharge), and clinical context (post-antibiotic therapy), and to select the correct targeted treatment rather than reflexively choosing antibiotics.